UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049412
Receipt number R000056213
Scientific Title Validation study of cancer detection system by circulating microRNA
Date of disclosure of the study information 2023/01/31
Last modified on 2023/05/03 09:57:00

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation study of cancer detection system by circulating microRNA

Acronym

Validation study of cancer detection system by circulating microRNA

Scientific Title

Validation study of cancer detection system by circulating microRNA

Scientific Title:Acronym

Validation study of cancer detection system by circulating microRNA

Region

Japan


Condition

Condition

Pancreatic cancer, biliary tract cancer, healthy control

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Validation of cancer detection system by circulating microRNA

Basic objectives2

Others

Basic objectives -Others

Validation of circulation microRNA detection system

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The difference in the logarithmic detection amount of each microRNA between the pancreatic/biliary cancer group and the healthy adult group.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Pancreatic/biliary cancer patient
Patients diagnosed with pathologically (cytological/histological) or suspicious on the image asinvasive pancreatic duct cancer, gallbladder cancer, intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or papillary carcinoma
Patients who can collect blood within 1 monthafter registration
Patients who have never undergone surgery or chemotherapy
Age 20+
No active malignant disease except pancreatic/biliary tract cancer
Healthy control
No history or complication of malignant disease, including carcinoma in situ or intramucosalcarcinoma
No history of hospitalization within the past 3months
Age 50+

Key exclusion criteria

none

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hiroko
Middle name
Last name Sudo

Organization

Toray Industries, Inc.

Division name

New Frontiers Research Laboratories

Zip code

248-8555

Address

6-10-1, Tebiro, Kamakura, Kanagawa

TEL

0467-32-9740

Email

Hiroko.sudo.u8@mail.toray


Public contact

Name of contact person

1st name Satoko
Middle name
Last name Takizawa

Organization

Toray Industries, Inc.

Division name

New Projects Development Division

Zip code

248-8555

Address

6-10-1, Tebiro, Kamakura, Kanagawa

TEL

0467-32-9740

Homepage URL


Email

satoko.takizawa.f3@mail.toray


Sponsor or person

Institute

Toray Industries, Inc.

Institute

Department

Personal name



Funding Source

Organization

Toray Industries, Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Human Tissue Samples Ethics Committee forR&D Toray Ind., Inc.

Address

1-1-1, Sonoyama Otsu, Shiga, 520-8558

Tel

077-533-8188

Email

hisashi.hashimoto.v8@mail.toray


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 01 Month 31 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2022 Year 08 Month 06 Day

Date of IRB

2022 Year 08 Month 24 Day

Anticipated trial start date

2022 Year 10 Month 24 Day

Last follow-up date

2023 Year 06 Month 30 Day

Date of closure to data entry

2023 Year 06 Month 30 Day

Date trial data considered complete

2023 Year 07 Month 30 Day

Date analysis concluded



Other

Other related information

Case-control study
Objects: Patients who visited a partner institution in October 2022 and met the selection criteria and gave IC


Management information

Registered date

2022 Year 11 Month 02 Day

Last modified on

2023 Year 05 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056213


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name